The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.本發明提供包含特異性結合至CD33之第一結合域及特異性結合至CD3之第二結合域之雙特異性建構體,其用於治療骨髓樣白血病之方法中,其中投與該建構體達最長14天之時段,然後至少14天之時段則不投與該建構體。此外,本發明提供用於治療骨髓樣白血病之方法,其包含投與治療有效量之該雙特異性建構體;及該雙特異性建構體之用途,其用於製備用來治療骨髓樣白血病之醫藥組合物。
